Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leniolisib: First Approval.

Drugs·2023
Same author

Correction to: Durvalumab: A Review in Extensive-Stage SCLC.

Targeted oncology·2021
Same author

Durvalumab: A Review in Extensive-Stage SCLC.

Targeted oncology·2021
Same author

Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.

Drugs·2021
Same author

Imlifidase: First Approval.

Drugs·2020
Same author

Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

Clinical drug investigation·2019
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K

Elsulfavirine: First Global Approval.

Zaina T Al-Salama1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|September 24, 2017
PubMed
Summary
This summary is machine-generated.

Elsulfavirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for HIV-1 treatment. This drug, a prodrug of VM-1500A, prevents HIV replication and is being studied for prevention.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Related Experiment Videos

Last Updated: Feb 22, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Elsulfavirine (Elpida®) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for human immunodeficiency virus (HIV) treatment and prevention.
  • It functions as a prodrug for the active metabolite VM-1500A, a selective NNRTI that inhibits HIV replication.

Purpose of the Study:

  • To summarize the key developmental milestones of elsulfavirine.
  • To highlight the drug's first global approval for HIV-1 treatment.

Main Methods:

  • Review of elsulfavirine's development pathway.
  • Analysis of preclinical and Phase II study evaluations.

Main Results:

  • Elsulfavirine received its first global approval in Russia in June 2017 for HIV-1 treatment.
  • The drug is being evaluated in various formulations for treatment and prophylaxis.

Conclusions:

  • Elsulfavirine represents a significant advancement in HIV therapy.
  • Ongoing studies are exploring its potential in HIV prevention (PrEP/PEP).